# Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients

> **NCT06648681** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of British Columbia** · enrollment: 60 (estimated)

## Conditions studied

- Delirium - Postoperative
- Cardiac Surgery
- Cardiac Surgery Subjects
- Orexin Antagonist
- Feasibility Studies
- Sleep
- In-hospital Mortality

## Interventions

- **DRUG:** Lemborexant 5 mg
- **DRUG:** Control (placebo) group

## Key facts

- **NCT ID:** NCT06648681
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06648681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06648681, "Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06648681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*